Tamer I. Khayal Sells 4,947 Shares of TransMedics Group, Inc. (NASDAQ:TMDX) Stock

TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) insider Tamer I. Khayal sold 4,947 shares of the stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $80.36, for a total transaction of $397,540.92. Following the completion of the transaction, the insider now owns 25,185 shares of the company's stock, valued at approximately $2,023,866.60. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

TransMedics Group Price Performance

NASDAQ:TMDX traded up $7.84 during mid-day trading on Friday, hitting $85.04. 1,117,719 shares of the company's stock traded hands, compared to its average volume of 657,415. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30. The firm's 50 day simple moving average is $82.28 and its 200 day simple moving average is $70.58. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $99.63. The company has a market cap of $2.78 billion, a PE ratio of -110.44 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.22. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $81.20 million for the quarter, compared to analysts' expectations of $68.49 million. During the same period last year, the company earned ($0.21) EPS. The firm's revenue for the quarter was up 158.6% compared to the same quarter last year. Sell-side analysts expect that TransMedics Group, Inc. will post -0.14 EPS for the current year.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. Comerica Bank acquired a new stake in shares of TransMedics Group during the 3rd quarter worth about $34,000. Ancora Advisors LLC acquired a new stake in shares of TransMedics Group during the 1st quarter worth about $38,000. Global Retirement Partners LLC acquired a new stake in shares of TransMedics Group during the 3rd quarter worth about $38,000. Cutler Group LLC CA boosted its stake in shares of TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company's stock worth $38,000 after purchasing an additional 600 shares during the last quarter. Finally, First Horizon Advisors Inc. boosted its position in shares of TransMedics Group by 45.1% in the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after acquiring an additional 169 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TMDX. Oppenheimer increased their price target on shares of TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a report on Tuesday, February 27th. JPMorgan Chase & Co. increased their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a report on Tuesday, February 27th. Piper Sandler began coverage on shares of TransMedics Group in a report on Thursday, March 28th. They issued an "overweight" rating and a $95.00 price target for the company. Finally, Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $102.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.